AstraZeneca’s Calquence shows strength in most common adult leukaemia

pharmafile | June 6, 2019 | News story | Research and Development AstraZeneca, Calquence, chronic lymphocytic leukaemia, pharma 

AstraZeneca has unveiled new Phase 3 data for Calquence (acalabrutinib) in treatment-naïve chronic lymphocytic leukaemia, showing that the drug met its primary endpoint when used in combination with obinutuzumab.

The data showed that Calquence use led to a “statistically-significant and clinically-meaningful improvement” in progression-free survival (PFS) compared to chemotherapy-based chlorambucil and obinutuzumab combo treatment, meeting its primary endpoint early

The study also met its secondary endpoint, improving PFS by a “statistically-significant and clinically-meaningful” margin compared to compared to a regimen of chemotherapy and obinutuzumab.

While specifics of the data were not revealed, AZ confirmed it would be presenting the full results at an upcoming medical meeting.

“These findings confirm the superiority of Calquence as a monotherapy and also in combination over standard-of-care treatments for chronic lymphocytic leukaemia,” commented José Baselga, AZ’s Executive Vice President, Oncology R&D.

The positive results from both the ELEVATE-TN and ASCEND trials will serve as the foundation for regulatory submissions later this year.”

Matt Fellows

Related Content

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …

Latest content